7SS logo

Brii Biosciences DB:7SS Stock Report

Last Price

€0.11

Market Cap

€87.7m

7D

11.8%

1Y

-52.5%

Updated

23 Dec, 2024

Data

Company Financials +

Brii Biosciences Limited

DB:7SS Stock Report

Market Cap: €87.7m

7SS Stock Overview

Engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. More details

7SS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 41.3% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 7.4% per year for the next 3 years

Does not have a meaningful market cap (€709M)

Volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Brii Biosciences Limited Competitors

Heidelberg Pharma

XTRA:HPHA

€101.6m

Medigene

XTRA:MDG1

€15.2m

2invest

XTRA:2INV

€67.3m

co.don

XTRA:CNW

€6.5m

Price History & Performance

Summary of share price highs, lows and changes for Brii Biosciences
Historical stock prices
Current Share PriceHK$0.11
52 Week HighHK$0.22
52 Week LowHK$0.096
Beta1.49
1 Month Change-2.56%
3 Month Change-0.87%
1 Year Change-52.50%
3 Year Change-97.29%
5 Year Changen/a
Change since IPO-94.61%

Recent News & Updates

Recent updates

Shareholder Returns

7SSDE BiotechsDE Market
7D11.8%-3.5%-2.0%
1Y-52.5%-14.7%6.9%

Return vs Industry: 7SS underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: 7SS underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 7SS's price volatile compared to industry and market?
7SS volatility
7SS Average Weekly Movement11.1%
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 7SS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 7SS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
201795Zhi Hongwww.briibio.com

Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease.

Brii Biosciences Limited Fundamentals Summary

How do Brii Biosciences's earnings and revenue compare to its market cap?
7SS fundamental statistics
Market cap€87.72m
Earnings (TTM)-€34.95m
Revenue (TTM)€5.05m

17.4x

P/S Ratio

-2.5x

P/E Ratio

Is 7SS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7SS income statement (TTM)
RevenueCN¥38.38m
Cost of RevenueCN¥0
Gross ProfitCN¥38.38m
Other ExpensesCN¥303.83m
Earnings-CN¥265.45m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.36
Gross Margin100.00%
Net Profit Margin-691.63%
Debt/Equity Ratio0%

How did 7SS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:52
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Brii Biosciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouChina International Capital Corporation Limited
Xiao Wei LinEverbright Securities Co. Ltd.
Geoffrey PorgesLeerink Partners LLC